Table 6.
Effect of silencing various pathways on cytotoxicity of classical anti-cancer drugs in 4T1 cells. Data is presented as mean ± SD compared to CA/drug.
| Treatment on 4T1 Cells | Drug Concentration | ||
|---|---|---|---|
| 10 pM | 100 pM | 1 nM | |
| CA/Pac/AKT | −15.93 ± 0.95 | 8.70 ± 2.14 | −2.68 ± 0.54 |
| CA/Pac/ERBB2 | 12.93 ± 0.36 | 9.15 ± 0.14 | 2.42 ± 2.84 |
| CA/Pac/MAPK | −13.79 ± 1.18 | 2.53 ± 0.20 | 2.16 ± 0.11 |
| CA/Pac/ROS1 | 10.09 ± 1.03 | 2.04 ± 0.85 | 7.24 ± 0.07 |
| CA/Doc/AKT | −5.04 ± 0.77 | −9.43 ± 0.51 | 1.30 ± 0.62 |
| CA/Doc/ERBB2 | 5.85 ± 1.08 | 7.21 ± 1.17 | 2.20 ± 1.95 |
| CA/Doc/MAPK | 3.16 ± 0.21 | 5.07 ± 0.98 | 2.67 ± 0.76 |
| CA/Doc/ROS1 | 2.76 ± 0.58 | 1.81 ± 0.97 | 0.05 ± 0.42 |
| CA/Mito/AKT | 0.20 ± 0.71 | 4.97 ± 1.15 | 1.92 ± 0.28 |
| CA/Mito/ERBB2 | 2.13 ± 3.64 | 5.11 ± 0.85 | 1.71 ± 0.38 |
| CA/Mito/MAPK | 1.26 ± 1.23 | 0.23 ± 1.45 | 7.77 ± 0.95 |
| CA/Mito/ROS1 | 0.72 ± 0.92 | 0.52 ± 0.16 | 4.20 ± 1.12 |
| CA/Topo/AKT | 0.02 ± 1.64 | 3.09 ± 0.42 | 5.28 ± 3.07 |
| CA/Topo/ERBB2 | 4.54 ± 2.27 | 5.85 ± 0.47 | 0.86 ± 2.51 |
| CA/Topo/MAPK | 6.54 ± 0.55 | 0.55 ± 0.51 | 4.74 ± 0.88 |
| CA/Topo/ROS1 | 0.58 ± 0.25 | 0.03 ± 0.36 | 0.52 ± 0.81 |
| CA/Pac/AKT/ERBB2 | 19.97 ± 1.73 | 5.48 ± 2.09 | 11.63 ± 2.23 |
| CA/Doc/AKT/ERBB2 | 7.87 ± 1.82 | 1.45 ± 0.37 | 15.16 ± 3.55 |
| CA/Mito/AKT/ERBB2 | 6.04 ± 0.28 | 0.59 ± 0.47 | 4.60 ± 0.82 |
| CA/Topo/AKT/ERBB2 | −10.41 ± 0.66 | −4.73 ± 1.52 | −10.77 ± 0.71 |